AN Venture Partners (ANV), a global biotech venture capital fund, is pleased to announce that its new portfolio company Crystalys Therapeutics (Crystalys), a clinical-stage biopharmaceutical company focused on transforming the treatment of gout by leveraging Japan’s excellence in pharmaceutical science with global expertise, has launched with a $205 million Series A financing co-led by Novo Holdings, SR One, and Catalys Pacific.
ANV is proud to be participating in this funding round as part of a broad syndicate of leading global investors, that also includes Perceptive Xontogeny Venture Funds, Lightstone Ventures and funds managed by abrdn.
The financing will support the advancement of Crystalys’ lead asset, dotinurad, a once-daily oral URAT1 inhibitor, into global Phase 3 clinical trials.
Dotinurad, originally discovered by Fuji Pharma, has already demonstrated robust safety and efficacy in extensive clinical studies and is approved in Japan, China, the Philippines and Thailand. This successful financing will enable Crystalys to accelerate efforts to address the unmet need for an effective second-line gout therapy in the US and Europe, where options are limited for patients who do not respond adequately to first-line treatments.
For the full announcement, please see Crystalys Therapeutics’ press release here.
For more information, please visit Crystalys Therapeutics’ website here.
About AN Venture Partners
ANV is a Tokyo and San Francisco-based multi-stage, global biotech venture capital firm specializing in bridging innovative science from Japan with the US start-up ecosystem. ANV Fund I is a USD200 million fund that closed in June 2025. The firm was established in 2022 by a group of experienced venture capitalists from Japan and the United States, who have a wealth of experience building start-ups. ANV is committed to strengthening Japan’s biotech ecosystem and founded initiatives such as Science2Startup Japan to accelerate ecosystem growth.
Media Contacts
Email: info@an.vc